UNC0 Stock Chart & Stats
€121.00
€0.00(0.00%)
At close: 4:00 PM EDT
€121.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€90.50 - €142.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€42.35B
Enterprise Value€61.29K
Total Cash (Recent Filing)€796.67M
Total Debt (Recent Filing)€3.59B
Price to Earnings (P/E)19.3
Beta0.54
Next Earnings
Feb 25, 2027EPS Estimate
2.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.81
Shares Outstanding389,011,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.66
Revenue Forecast (FY)€8.58B
Bulls Say, Bears Say
Bulls Say
Cash GenerationMaterial improvement in operating and free cash flow provides durable funding for R&D, commercialization and inorganic growth, enhances ability to absorb product lifecycle shocks, and supports ongoing investment without relying on volatile external financing.
BIMZELX Momentum & Diversified GrowthBIMZELX's rapid multi-indication adoption and high market shares establish a durable commercial engine. Broad approvals, sizeable patient uptake, and reiterated multi‑billion peak potential underpin long-term top-line resilience and reduce single-product concentration risk.
Balance Sheet ImprovementDeclining debt and a stronger equity base improve financial flexibility, lowering refinancing and liquidity risk. This strengthens capacity to fund pipeline development, manage LOE effects, and absorb integration costs without destabilizing capital structure.
Bears Say
BRIVIACT Loss Of ExclusivityA steep, multi‑quarter decline from BRIVIACT LOE creates a sustained revenue gap that must be replaced by product growth or cost reductions. Given its size, the loss stresses near‑term operating leverage and forces durable reallocation of commercial and R&D resources.
Margin Pressure / Lower EBITEarnings quality is challenged when EBIT falls even as revenue rises; persistent margin compression would erode free cash flow and limit reinvestment. If higher SG&A, integration or pricing pressure persists, sustaining profitability could require structural cost action.
Higher Leverage & Integration Interest CostsIncreased net debt and expected higher interest plus integration spending raise fixed costs and reduce financial headroom. This constrains flexibility to fund pipeline or absorb pricing shocks and makes margins more sensitive to revenue volatility over the medium term.
UCB SA News
UNC0 FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was €90.50 and its highest was €142.00 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is €42.35B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Feb 25, 2027 which is in 205 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Jul 30, 2026. The company reported €3.411 earnings per share for the quarter, beating the consensus estimate of €2.522 by €0.889.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA does not currently pay dividends.
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 2.61.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of €3.411 in its last earnings report, beating expectations of €2.522. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in DE:UNC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:UNC0 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.10%
12-Months-Change
Fundamentals
Return on Equity
0.66%
Trailing 12-Months
Asset Growth
18.72%
Trailing 12-Months
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
UNC0 Company Deck
UNC0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance in H1 2026: robust top-line growth, expanding margins and EBITDA, upgraded guidance, and clear commercial momentum for key growth drivers (notably BIMZELX) alongside meaningful pipeline and strategic acquisitions positioning the company for sustained longer-term growth. Notable risks include BRIVIACT loss of exclusivity with large expected sales declines, anticipated net price pressure from recent access wins (near-term H2 price erosion before volume benefits), increased G&A and integration costs from acquisitions, and competition/heterogeneity risks in HS. On balance, the positive execution, upgraded guidance and attractive pipeline developments outweigh the near-term headwinds.View all DE:UNC0 earnings summaries